Protagenic Therapeutics Return on Equity

Protagenic Therapeutics (PTIX) currently reports a ROE of 316.93%. That is above the Industrials sector average of 20.55%. Use the charts on this page to explore Protagenic Therapeutics's ROE history and peer comparisons.

Protagenic Therapeutics's ROE of 316.93% is higher than the Industrials sector average of 20.55%. That is roughly 1442.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Protagenic Therapeutics's current 316.93% should be judged against Industrials norms (sector average: 20.55%) and against PTIX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 316.93%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Industrials average is 20.55%. From there, open related valuation or income-statement pages for Protagenic Therapeutics, and consider following PTIX for alerts when major investors trade the stock.

Protagenic Therapeutics is classified in the Industrials sector. On ROE, it currently shows 316.93% versus a sector average near 20.55%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Industrials are usually more informative than comparing PTIX with unrelated industries.